​

OncoCyte (OCX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

OCX Stock Forecast

OncoCyte (OCX) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $8.08, with a high of $10.00 and a low of $4.25. This represents a 300.00% increase from the last price of $2.02.

$2 $3 $4 $5 $6 $7 $8 $9 $10 High: $10 Avg: $8.08 Low: $4.25 Last Closed Price: $2.02

OCX Stock Rating

OncoCyte stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

OCX Forecast vs Benchmarks

TypeNameUpside
StockOncoCyte300.00%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$4.25
Last Closing Price$2.02$2.02$2.02
Upside/Downside--110.40%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 251-2--3
Dec, 241-2--3
Nov, 24132--6
Oct, 24133--7
Sep, 24133--7
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 24, 2024Mike MatsonNeedham$4.25$2.3878.57%110.40%
Dec 01, 2022Lake Street$10.00$9.445.93%395.05%
Nov 18, 2022Piper Sandler$10.00$8.5217.37%395.05%
Aug 17, 2022David WestenbergPiper Sandler$30.00$17.4871.62%1385.15%
Aug 11, 2022Lake Street$60.00$19.27211.36%2870.30%
Aug 11, 2022Needham$42.00$19.02120.82%1979.21%
May 15, 2022David WestenbergPiper Sandler$28.00$22.6023.89%1286.14%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 15, 2024NeedhamBuyBuyhold
May 16, 2024StephensBuyBuyhold
Apr 24, 2024NeedhamBuyBuyhold
Nov 18, 2022Piper SandlerOverweightNeutraldowngrade
Nov 14, 2022Piper SandlerOverweightOverweighthold
Nov 11, 2022NeedhamBuyBuyhold
Aug 17, 2022Piper SandlerOverweightOverweighthold
Aug 11, 2022Lake StreetBuyBuyhold
Aug 11, 2022NeedhamBuyBuyhold
May 15, 2022Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-9.14$-14.42$-13.26$-3.63---
Avg Forecast$-9.65$-8.20$-7.17$-1.30$-2.74$-1.54$-1.36
High Forecast$-11.44$-9.72$-9.41$-1.90$-4.01$-2.25$-1.55
Low Forecast$-7.49$-6.36$-4.52$-0.59$-1.24$-0.69$-1.16
Surprise %-5.28%75.85%84.94%179.23%---

Revenue Forecast

$0 $2M $4M $5M $7M $9M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$1.22M$7.73M$958.00K$1.50M---
Avg Forecast$1.50M$7.82M$5.94M$1.42M$500.00K$1.03M$5.70M
High Forecast$1.24M$6.47M$4.25M$820.01K$288.84K$596.16K$3.29M
Low Forecast$1.71M$8.93M$7.37M$1.93M$678.25K$1.40M$7.73M
Surprise %-18.96%-1.16%-83.87%5.88%---

Net Income Forecast

$-90M $-73M $-56M $-39M $-22M $-5M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-29.93M$-64.10M$-73.44M$-27.78M---
Avg Forecast$-73.83M$-62.74M$-34.66M$-25.80M$-20.07M$-11.25M$-10.37M
High Forecast$-87.49M$-74.35M$-41.60M$-30.96M$-30.68M$-17.21M$-11.86M
Low Forecast$-57.30M$-48.69M$-27.73M$-20.64M$-9.45M$-5.30M$-8.88M
Surprise %-59.46%2.17%111.86%7.69%---

OCX Forecast FAQ

Is OncoCyte stock a buy?

OncoCyte stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that OncoCyte is a favorable investment for most analysts.

What is OncoCyte's price target?

OncoCyte's price target, set by 4 Wall Street analysts, averages $8.08 over the next 12 months. The price target range spans from $4.25 at the low end to $10 at the high end, suggesting a potential 300.00% change from the previous close price of $2.02.

How does OncoCyte stock forecast compare to the average forecast of its sector, industry, and investment themes?

OncoCyte stock forecast shows a 300.00% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for OncoCyte over the past three months?

  • January 2025: 33.33% Strong Buy, 0% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 33.33% Strong Buy, 0% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 16.67% Strong Buy, 50.00% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is OncoCyte’s EPS forecast?

OncoCyte's average annual EPS forecast for its fiscal year ending in December is -2.74 for 2024, a -24.52% decrease from the reported $-3.63 in 2023. The prediction for 2025 is $-1.54, and $-1.36 for 2026.

What is OncoCyte’s revenue forecast?

OncoCyte's average annual revenue forecast for its fiscal year ending in December is $500K for 2024, a -66.73% decrease from the reported $1.5M in 2023. The forecast for 2025 is $1.03M, and $5.7M for 2026.

What is OncoCyte’s net income forecast?

For its fiscal year ending in December, OncoCyte's average annual net income forecast is $-20.067M for 2024, reflecting a -27.77% decrease from the reported $-27.781M in 2023. The projection for 2025 is $-11.254M, and $-10.367M for 2026.